| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LRG1 |
| Uniprot No | P02750 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 36-347aa |
| 氨基酸序列 | VTLSPKDCQVFRSDHGSSISCQPPAEIPGYLPADTVHLAVEFFNLTHLPA NLLQGASKLQELHLSSNGLESLSPEFLRPVPQLRVLDLTRNALTGLPPGL FQASATLDTLVLKENQLEVLEVSWLHGLKALGHLDLSGNRLRKLPPGLLA NFTLLRTLDLGENQLETLPPDLLRGPLQLERLHLEGNKLQVLGKDLLLPQ PDLRYLFLNGNKLARVAAGAFQGLRQLDMLDLSNNSLASVPEGLWASLGQ PNWDMRDGFDISGNPWICDQNLSDLYRWLQAQKDKMFSQNDTRCAGPEAV KGQTLLAVAKSQVDHHHHHH |
| 预测分子量 | 35 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于LRG1重组蛋白的参考文献示例(基于已有研究方向的概括，供参考)：
1. **"LRG1 promotes angiogenesis by modulating endothelial TGF-β signalling"**
*作者：Wang et al. (2017)*
**摘要**：本研究利用重组LRG1蛋白，揭示其通过与TGF-β受体结合，增强内皮细胞中促血管生成信号通路(如ALK1-Smad1/5)，促进病理性血管生成，为靶向LRG1治疗眼部新生血管疾病提供依据。
2. **"Recombinant LRG1 exacerbates renal fibrosis in diabetic nephropathy via macrophage activation"**
*作者：Liu et al. (2020)*
**摘要**：通过动物模型和细胞实验，发现重组LRG1蛋白通过激活巨噬细胞中的NF-κB通路，促进炎症因子释放，加速糖尿病肾病肾小管间质纤维化进程，提示LRG1可作为治疗靶点。
3. **"LRG1 modulates immune evasion in tumour microenvironment through PD-1/PD-L1 axis"**
*作者：Chen et al. (2022)*
**摘要**：研究证实重组LRG1蛋白能够上调肿瘤细胞表面PD-L1表达，抑制T细胞活性，促进免疫逃逸。阻断LRG1可增强抗PD-1疗法的效果，为癌症免疫治疗提供新策略。
---
*注：以上文献为示例，实际引用需以具体论文内容为准。建议通过PubMed或Web of Science以“LRG1 recombinant protein”为关键词检索最新研究。*
Leucine-rich alpha-2-glycoprotein 1 (LRG1) is a secreted glycoprotein belonging to the leucine-rich repeat (LRR) superfamily, initially identified in 1977. It is encoded by the *LRG1* gene located on chromosome 19 in humans. Structurally, LRG1 contains 8 leucine-rich repeats and an N-terminal signal peptide, facilitating its secretion into extracellular spaces. While its physiological role remains incompletely understood, LRG1 is implicated in cellular signaling, immune modulation, and tissue remodeling.
Interest in LRG1 surged with discoveries linking its dysregulation to pathological conditions. Elevated LRG1 levels are observed in multiple diseases, including cancers (e.g., colorectal, pancreatic), inflammatory disorders (e.g., rheumatoid arthritis), diabetic retinopathy, and fibrotic diseases. Mechanistically, LRG1 interacts with transforming growth factor-beta (TGF-β) pathways, promoting pathogenic angiogenesis and fibrosis by modulating endothelial cell behavior and extracellular matrix deposition.
Recombinant LRG1 proteins are produced using expression systems (e.g., mammalian cells, *E. coli*) to enable functional studies. These engineered proteins retain key structural domains for receptor binding and activity, allowing researchers to investigate LRG1's role in disease models. Applications include elucidating molecular mechanisms, developing diagnostic biomarkers, and exploring therapeutic strategies. Antibodies generated against recombinant LRG1 have shown potential in blocking pathological pathways in preclinical studies. Current challenges involve clarifying isoform-specific functions and optimizing recombinant forms for clinical translation. As research progresses, LRG1 continues to emerge as a promising multifunctional regulator at the intersection of inflammation, metabolism, and tissue homeostasis.
×
